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Abstract
Natural human embryonic mortality is generally considered to be high. Values
of 70% and higher are widely cited. However, it is difficult to determine
accurately owing to an absence of direct data quantifying embryo loss between
fertilisation and implantation. The best available data for quantifying pregnancy
loss come from three published prospective studies (Wilcox, Zinaman and
Wang) with daily cycle by cycle monitoring of human chorionic gonadotrophin
(hCG) in women attempting to conceive. Declining conception rates cycle by
cycle in these studies indicate that a proportion of the study participants were
sub-fertile. Hence, estimates of fecundability and pre-implantation embryo
mortality obtained from the whole study cohort will inevitably be biased. This
new re-analysis of aggregate data from these studies confirms the impression
that discrete fertile and sub-fertile sub-cohorts were present. The proportion of
sub-fertile women in the three studies was estimated as 28.1% (Wilcox), 22.8%
(Zinaman) and 6.0% (Wang). The probability of conceiving an hCG pregnancy
(indicating embryo implantation) was, respectively, 43.2%, 38.1% and 46.2%
among normally fertile women, and 7.6%, 2.5% and 4.7% among sub-fertile
women. Pre-implantation loss is impossible to calculate directly from available
data although plausible limits can be estimated. Based on this new analysis
and a model for evaluating reproductive success and failure it is proposed that
a plausible range for normal human embryo and fetal mortality from fertilisation
to birth is 40-60%.
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Introduction
Estimates of natural human embryo mortality have been derived 
using speculative calculations1, mathematical modelling2, 
pregnancy surveys3, and a unique collection of surgical material4,5. 
Three well-designed studies (henceforth referred to as the 
Wilcox6, Zinaman7 and Wang8 studies) have shown that approxi-
mately two-thirds of menstrual cycles in which elevated human 
chorionic gonadotrophin (hCG) is detected approximately 1 week 
after ovulation proceed to a live birth. hCG is produced by the 
trophoblast cells of the embryo9 and its earliest detection indicates 
that implantation has commenced10–12. Hence, these studies provide 
no direct measure of embryo loss before implantation. The only 
measure of pre-implantation loss is the “scanty data of Hertig”13 
which have generated estimates4,5 that are “difficult to defend with 
any precision”2. Estimates of embryo mortality from fertilisation 
onwards are therefore subject to considerable uncertainty owing 
to the absence of suitable data for the 5–7 day period between 
fertilisation and implantation.
Fecundability is the probability of reproductive success per cycle. 
Compared to other animals, fecundability in humans is low and 
has been estimated at <35%14,15. Red deer hinds, by contrast, 
achieve pregnancy rates of >85% per natural mating16. Clearly, as 
fecundability increases, the range of plausible values for embryo 
mortality narrows. Crude estimates of live birth fecundability can 
be calculated from prospective study data: 19.2% (136 births from 
707 cycles6), 18.2% (79 births from 432 cycles7) and 23.9–25.9% 
(373 births and 31 ongoing pregnancies from 1,561 cycles8). These 
represent lower limits for fecundability, since optimal condi-
tions for reproductive success were not achieved in every cycle17. 
However, some published estimates of embryo mortality, e.g., 
76%2,18 and 78%1 can only be reconciled with these data if it is 
assumed that almost every non-birth cycle in these studies resulted 
in successful fertilisation and subsequent embryonic or fetal death, 
an extreme and improbable condition. Higher estimates of embryo 
mortality, including >85%19 and 90%20, are even less plausible. 
Furthermore, it is self-evident that not all observed reproductive 
failure is necessarily due to embryo or fetal mortality: other biologi-
cal causes include mistimed coitus and failure of fertilisation despite 
in vivo co-localisation of ovum and sperm. Estimates of embryo 
mortality based on fecundability must take this into account.
The objective of this study is to obtain plausible estimates of 
fecundability and early human embryo mortality from available 
published data6–8. To do this, a simple quantitative framework is 
proposed to define a successful reproductive cycle. Hence, for a 
menstrual cycle to conclude with a live infant several distinct 
biological stages must be completed, each with its own prob-
ability (π) of success. These stages (and conditional probabilities) 
are defined as follows: (1) sexual activity within a cycle resulting 
in sperm-ovum-co-localisation (πSOC); (2) subsequent successful 
fertilisation (πFERT); (3) initiation of implantation approximately 
1 week after fertilisation as indicated by increased levels of 
hCG (πHCG); (4) progression to a clinical pregnancy (πCLIN): the 
earliest typical clinical indication is an absent menstrual period 
approximately 14 days after fertilisation, although definitions of 
clinical pregnancy vary between studies; (5) survival of a clinical 
pregnancy to a live birth (πLB). Conditional probabilities are defined 
more formally as follows:
If P(A|B) is the probability of event A, conditional on event 
B, then:
  i. πLB    = P(A|B), where A is a live birth, and B is a clini-
cal pregnancy
 ii. πCLIN = P(A|B), where A is a clinical pregnancy, and B 
is a positive hCG test
iii. πHCG = P(A|B), where A is a positive hCG test, and B 
is successful fertilisation
iv. πFERT = P(A|B), where A is successful fertilisation, and 
B is the in vivo co-localisation of ovum and sperm 
 v. πSOC  = P(A|B), where A is the in vivo co-localisation 
of ovum and sperm, and B a single menstrual cycle
It is therefore possible to calculate four different fecundabilities 
(broadly following Leridon21): 
1. Total (All fertilisations):     FECTOT = πSOC × πFERT 
2. Detectable (Implantation): FECHCG = πSOC × πFERT × πHCG 
3.  Apparent (Clinical):           FECCLIN = πSOC × πFERT × πHCG × πCLIN
4.  Effective (Live Birth):         FECLB  = πSOC × πFERT × πHCG × πCLIN × πLB
Quantitative differences between these fecundabilities reflect 
intrauterine mortality at different developmental stages. Hence, the 
probability that a fertilised egg will perish prior to implantation is 
[1 − πHCG], and prior to clinical recognition is [1 – (πHCG × πCLIN)]. In 
theory, embryonic mortality may be estimated at all stages although 
in practice this depends on available data.
In 1969, Barrett & Marshall analysed the relationship between 
coital patterns and conception and concluded that fecundability 
increased with coital frequency up to 68% for daily intercourse22. 
Schwartz’s re-analysis of the same data revealed a similar pat-
tern, although at higher coital frequencies estimated fecundability 
was lower, at 49% for daily intercourse23. These analyses indicate 
that failure to conceive at coital frequencies of less than once per 
day is, in part, due to mistimed coitus and not solely failure of 
fertilisation and/or embryo mortality. The difference in their esti-
mates of fecundability arises because of key differences between 
the two analyses. Firstly, Schwartz analysed 2,192 cycles, 294 
more than Barrett & Marshall. Secondly, the measures of concep-
tion differed: Barrett & Marshall used “absence of menstruation, 
after ovulation”, approximately 2 weeks after ovulation, whereas 
for Schwartz conception was “defined as a pregnancy lasting at 
least 2 months from the last menstrual period”, i.e., approximately 
6 weeks from the day of ovulation. It is not surprising therefore 
            Amendments from Version 1
This new version includes more formal definitions of conditional 
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clarify the meaning of the estimates. 
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that Schwartz values were lower since they will not have captured 
pregnancies that failed between 2 and 6 weeks post-fertilisation. 
Thirdly, and importantly, Schwartz introduced a new term, ‘cycle 
viability’, into the analytical model.
Schwartz modelled the probability of conceiving during a cycle 
(i.e., fecundability, FEC) as the product of three conditional 
probabilities as follows: FEC = PoPfPv. Po, Pf and Pv were the prob-
abilities that (i) a fertilisable egg is produced (Po), (ii) it is fertilised 
once produced (Pf), and (iii) it survives to be detected as a concep-
tion (Pv). Pf  was modelled as a function of coital frequency. Cycle 
viability (k) was defined as k = PoPv, and allows for the possibility 
that optimally-timed coitus would not result in a detected concep-
tion. It implies that there is a proportion of cycles that are infertile 
irrespective of coital activity. Although Schwartz did not explic-
itly report statistical data demonstrating that the extra parameter 
(k = 52%) improved the quality of the model, a comparison of the 
Barrett & Marshall and Schwartz models using the Wilcox study 
data6 provided compelling statistical evidence to this effect, and 
concluded that only 37% of cycles were ‘viable’24.
Since cycle viability (k) includes terms defining reproductive suc-
cess both before (Po = successful ovulation) and after (Pv = embryo 
survival) fertilisation, it is not possible to use this term to make 
direct inferences about early embryo mortality. Nevertheless, 
Schwartz assumed that Po = 100%, thereby interpreting all cycle 
non-viability as a consequence of embryo loss at a rate of 48% 
during the first 6 weeks after fertilisation. Similar logic applied 
to the Wilcox study24 would conclude an equivalent estimate of 
63% embryo mortality. Schwartz also concluded that Pf  = 94% for 
daily intercourse (0.49/0.52). Hence, Schwartz attributed almost 
all the observed reproductive inefficiency to embryo mortality and 
other processes of the reproductive process were, by implication, 
considered to work almost perfectly. By contrast, referring to 
fertilisation, Hertig noted that “it seems unlikely that such a 
complicated process should work perfectly every time”5. It has 
also been correctly pointed out that preimplantation loss is statis-
tically indistinguishable from other causes of cycle non-viability 
including male factors15. It seems that this interpretation of repro-
ductive inefficiency has contributed to a widespread impression 
that early human embryo mortality is very high.
What are the potential explanations for cycle non-viability? 
Incorporation of a between-couple random effect into the model-
ling of these data has confirmed that cycle viability is heterogene-
ous between couples15. A subject-specific random effects modelling 
approach also resulted in a more consistent cycle by cycle esti-
mate of cycle viability25. These analyses formally demonstrate that 
within the cohorts of women used in this study, there were individ-
ual differences in fecundability. Furthermore, in the Wilcox study, 
14 out of 221 women were unable to conceive within 24 months6: 
this observation alone suggests that a proportion of the study 
participants were sub-fertile.
Each of the three hCG studies sought to recruit normally fertile, 
non-contracepting women who intended to conceive. Subjects 
either had “no known fertility problems”6, or were excluded if 
they had any “known risk factors for infertility”7 or “had tried 
unsuccessfully to get pregnant for ≥1 year at any time in the past”8. 
However, such criteria cannot guarantee complete exclusion of 
sub-fertile or infertile couples, and in each study pregnancy rates 
declined in successive cycles as the presumed proportion of sub-
fertile women remaining increased. Hence, calculations based on 
overall aggregate data underestimate fecundability in normally fer-
tile women. Even estimates based on first cycle data are likely to be 
biased since a proportion of sub-fertile of women would be in the 
starting cohort. The extent of the bias of such estimates will depend 
on factors including the heterogeneity of the population and the 
number of cycles studied.
Estimates for FECHCG of 30%7 and 40%8, and for FECCLIN of 30%8 
and 25%6 probably underestimate the fecundability of reproduc-
tively healthy women owing to a mixed fertile/sub-fertile population 
in these studies. The object of the present analysis was to determine 
whether the published aggregate data supported this hypothesis 
and to estimate fecundability for any sub-cohorts identified. The 
modelling approach is conceptually simple; nevertheless, the 
results strongly indicate that the hypothesis is true and therefore 
provide less biased estimates of fecundability for reproductively 
normal women. These higher estimates of fecundability narrow 
the range of plausible values for embryo mortality in normal fertile 
women.
Methods
Data were obtained from Table 2 of Wilcox6, Table 3 and Figure 1 
of Zinaman7 and Table 2 of Wang8 studies. Fourteen women who 
did not conceive after 24 months were included in the analysis of 
the Wilcox data (1 reproductive cycle per month was assumed). A 
subsequent publication reported an extra cycle and an extra hCG 
pregnancy26; however, it is not clear in which cycle this occurred, 
Table 1. Parameter values and statistical output from best 
fit models (Model 0) of the data from Wilcox (1988), Zinaman 
(1996) and Wang (2003) studies. Probabilities and percentages 
were estimated as logits (base 10). Standard errors are shown. 
Actual probabilities with 95% confidence intervals are reported in 
Figure 1. Two alternatively parameterised (Model 0 & Model 00) but 
statistically identical models were used to obtain standard errors for 
FECHCG and FECCLIN since FECCLIN = FECHCG × πCLIN (ELS = extended 
least squares; dof = degrees of freedom.)
Parameter Wilcox (1988) Zinaman (1996) Wang (2003)
%fert(1) 
FECHCG/FERT 
FECCLIN/FERT 
FECHCG/SUBF 
FECCLIN/SUBF 
πCLIN
σ 
γ 
0.408 ± 0.085
-0.118 ± 0.066
-0.291 ± 0.043
-1.087 ± 0.091
-1.200 ± 0.086
0.558 ± 0.099
0.437 ± 0.090
1.26 ± 0.14
0.529 ± 0.145
-0.211 ± 0.049
-0.301 ± 0.057
-1.598 ± 0.476
-1.657 ± 0.477
0.845 ± 0.165
1.250 ± 0.686
0.47 ± 0.37
1.194 ± 0.167
-0.066 ± 0.029
-0.271 ± 0.018
-1.304 ± 0.383
-1.431 ± 0.378
0.488 ± 0.043
0.870 ± 0.193
0.84 ± 0.13
N 
parameters
dof
ELS 
27
6
21
52.6707
26
6
20
73.0862
41
6
35
119.209
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Table 2. Statistical results of hypothesis tests comparing the models shown in Table 1 (Model 0) with alternative 
models. Degrees of freedom (dof) is the difference in the number of estimated parameters between the models. χ2 is the 
difference in objective function values (ELS) for the two models. P values were calculated using likelihood ratio tests. The 
models are defined in brackets. H0 is the null hypothesis. H1 is the alternative hypothesis. NONMEM control files are named 
according to the study and the model, e.g., Model 0 for the Wang data is WANG0.ctl.
Hypothesis 
Test H0  H1  dof
Wilcox (1988) 
χ2, P 
Zinaman (1996) 
χ2, P 
Wang (2003) 
χ2, P 
1
FECHCG/FERT = FECHCG/SUBF 
(Model 1)
FECHCG/FERT ≠ FECHCG/SUBF 
(Model 0)
2 54.0, 2 × 10-12 54.9, 1 × 10-12 69.5, 8 × 10-16 
2
2 FECHCG sub-cohorts 
(Model 0)
3 FECHCG sub-cohorts 
(Model 2)
2 0.00, 1.00 0.65, 0.72 0.00, 1.00
3
2 FECHCG sub-cohorts 
1 πCLIN sub-cohort 
(Model 0)
3 FECHCG sub-cohorts 
3 πCLIN sub-cohorts 
(Model 3)
4 0.30, 0.99 1.49, 0.83 0.64, 0.96
4
γ = 0 
(Model 4)
γ ≠ 0 
(Model 0)
1 34.3, 5 × 10-9 1.64, 0.20 42.8, 6 × 10-11 
Table 3. Estimates of conditional probabilities for different stages of the reproductive process for 
reproductively normal subjects. Estimates of hCG (FECHCG) and clinical (FECCLIN) fecundabilities and πCLIN are 
derived from three hCG pregnancy studies as described in the text. πLB is calculated from published values in 
Wilcox6, Zinaman7 and Wang8 study reports. Estimates of fertilised egg loss up to implantation, clinical recognition 
and birth are provided, based on three scenarios: (i) high implantation probability (πHCG = 90%); (ii) equal 
implantation and fertilisation probabilities (πFERT = πHCG); (iii) high fertilisation probability (πFERT = 90%). The probability 
of sperm-ovum-co-localisation (πSOC) was assumed to be 0.80.
Derived Fecundabilities and Conditional 
Probabilities For Fertile Women
Wilcox (1988) Zinaman (1996) Wang (2003)
FECHCG 
FECCLIN 
πCLIN 
πLB 
0.432
0.339
0.783
0.877
0.381
0.333
0.875
0.790
0.462
0.349
0.754
0.871
% loss from implantation to live birth 31.3 30.9 34.2
If πSOC = 0.80, then πFERT × πHCG =
If πFERT = πHCG, then πFERT = πHCG =
If πFERT = 0.90, then πHCG =
If πHCG = 0.90, then πFERT =
0.540
0.735 
0.600 
0.476
0.690 
0.529 
0.578
0.760 
0.642 
Estimated losses of fertilised eggs when…
πHCG 
= 
0.90
πFERT 
= 
πHCG
πFERT 
= 
0.90
πHCG 
= 
0.90
πFERT 
= 
πHCG 
πFERT 
= 
0.90
πHCG 
= 
0.90
πFERT 
= 
πHCG 
πFERT 
= 
0.90
% loss before implantation
% loss before clinical recognition
% loss before live birth
10.0
29.5
38.2
26.5
42.4
49.5
40.0
53.0
58.7
10.0
21.3
37.8
31.0
39.6
52.3
47.1
53.7
63.4
10.0
32.1
40.8
24.0
42.7
50.0
35.8
51.6
57.8
Page 4 of 16
F1000Research 2016, 5:2083 Last updated: 06 DEC 2016
Figure 1. Graphical representation of data and best fit models for Wilcox (A, D, G), Zinaman (B, E, H) and Wang (C, F, I) studies. Each 
panel shows the data value from the study for each point ( = women starting cycle; + = hCG pregnancies; × = clinical pregnancies). The line 
indicates the best fit models as defined in Table 1. Parameter estimates and [95% confidence intervals] from these models are also shown.
Page 5 of 16
F1000Research 2016, 5:2083 Last updated: 06 DEC 2016
and so the original report data6 have been used. In Wilcox and 
Wang, for each study cycle, the number of (i) women starting 
each cycle, (ii) hCG pregnancies, and (iii) clinical pregnancies 
were recorded. The number of women who finished the study 
without becoming clinically pregnant and the number of women 
who dropped out at the end of each cycle were also reported. Women 
who conceived an hCG positive pregnancy but not a clinical preg-
nancy in a cycle continued in the study. Wilcox reported data for a 
maximum of nine cycles per subject and Wang for 14. The Zinaman 
study was similar, except that hCG data were obtained for only the 
first three study cycles. In the subsequent nine cycles only clinical 
pregnancy was recorded. Also, only the first pregnancy, whether 
hCG or clinical was reported.
Observed data were modelled to estimate the following parameters: 
(1) %fert(1) = the percentage of fertile women in the starting cohort; 
(2) FECHCG = the probability of conceiving an hCG pregnancy per 
cycle; (3) FECCLIN the probability of becoming clinically pregnant 
per cycle. Alternative parameterisation allowed the probability of an 
hCG pregnancy progressing to a clinical pregnancy (πCLIN) to also 
be determined. The percentage of sub-fertile women in the starting 
cohort was %subf(1) = 100% – %fert(1). FECHCG, FECCLIN and πCLIN 
were determined for both fertile and sub-fertile sub-cohorts. The 
following expressions define the relationship between the param-
eters and the modelled estimates.
  NFERT(#) = N(#) × %fert(#)            (1)
  NSUBF(#) = N(#) − NFERT(#)           (2)
  PREGHCG/FERT(#) = NFERT(#) × FECHCG/FERT          (3)
  PREGCLIN/FERT(#) = NFERT(#) × FECHCG/FERT × πCLIN/FERT                 (4)
  FECCLIN/FERT = FECHCG/FERT × πCLIN/FERT                            (5)
  PREGCLIN(#) = PREGCLIN/FERT(#) + PREGCLIN/SUBF(#)               (6)
  N(#+1) = N(#) − PREGCLIN(#) − FIN(#) − DROP(#)                             (7)
 %fert(#+1) = (NFERT(#) − PREGCLIN/FERT(#)) ÷ (N(#) − PREGCLIN(#))        (8)
 NONPREG(#)= [NFERT(1) × (1−FECCLIN/FERT)#] + [NSUBF(1) × (1−FECCLIN/SUBF)#]   (9)
Where: N(#) is the number of women starting cycle # (for cycle 1, 
N(1) was fixed for each set of study data; Wilcox = 221; Zinaman = 
200; Wang = 518); NFERT(#) and NSUBF(#) are the modelled number 
of fertile and sub-fertile women starting cycle #; PREGHCG/FERT(#) 
and PREGCLIN/FERT(#) are predicted numbers of hCG and clinical 
pregnancies in fertile women in cycle # (and analogously for 
sub-fertile women); FIN(#) is the number of women who finished 
the study without becoming clinically pregnant in cycle #; DROP(#) 
is the number of women who withdrew from the study at the end 
of cycle #; %fert(#) is the percentage of women starting cycle # who 
were fertile (and analogously for sub-fertile women); NONPREG(#) 
is the number of non-pregnant women after # cycles (equation (9) 
was only used to incorporate 14 non-pregnant women after 
24 months into the Wilcox data model). Model expansion to 
allow three fertility sub-cohorts and contraction to a single fertility 
sub-cohort enabled hypotheses about parameters and sub-cohorts 
to be statistically evaluated.
All probabilities and percentages were estimated as logits (base 
10). Residual unexplained variance (RUV) was modelled as a 
function of predicted values (PRED) as follows: 
 RUV = σ 2 × PREDγ           (10)
…where σ is an estimated parameter defining residual error and 
γ a coefficient defining the relationship between the dependent 
variables and PRED. When γ = 0, the residual model is homo-
scedastic. When γ = 2, the residual coefficient of variation is a 
constant.
Data were analysed with NONMEM 7.3.0 (Icon PLC, Dublin, 
Eire) and implemented using Wings for NONMEM (http://wfn.
sourceforge.net/). Parameters were estimated using a maximum 
likelihood algorithm (First Order Conditional Estimate with 
Interaction) and standard errors derived using the inverse 
Hessian (MATRIX = R). The objective function in NONMEM 
is the Extended Least Squares (ELS)27. Statistical hypotheses of 
nested models (Table 2) were tested using likelihood ratio tests 
(LRT). Control and data files are available online. Control files are 
named from the study and the model, e.g., WANG0.ctl is the control 
file for Model 0 applied to the Wang study data.
Results
Figure 1 shows the original data values and the fitted models plot-
ted by cycle. Parameter estimates are also shown and output from 
the models is given in Table 1. These models incorporate discrete 
fertile and sub-fertile sub-cohorts with differing FECHCG but com-
mon πCLIN values. Statistical comparison of alternative models 
strongly indicated that reducing the dimensionality of the model 
to a single FECHCG value substantially reduced its quality (Table 2, 
Hypothesis 1), whereas expanding the model to allow for three 
different FECHCG values did not improve the quality of the model 
(Table 2, Hypothesis 2). These statistical results indicate that the 
data are consistent with bi-modal study populations comprising 
two distinct fertility sub-cohorts. There was no statistical indication 
that πCLIN differed between these sub-cohorts (Table 2, Hypothesis 3). 
Evidence for heteroscedasticity in the residual error was strong 
for the Wilcox and Wang studies, and weak for the Zinaman study 
(Table 2, Hypothesis 4).
Figure 2 illustrates the estimated parameter values. Notwithstanding 
the differences between the studies, there is considerable agree-
ment in the estimates. One noteworthy difference is in the pro-
portion of sub-fertile women. This was low (6.0%) in the Wang 
study compared to the other two which were approximately 25%. 
Zinaman et al. commented on the high proportion of appar-
ently infertile women in their study despite their efforts during 
recruitment7. The estimate of 22.8% sub-fertile women is con-
sistent with their estimate of 18% infertility, bearing in mind that 
sub-fertile women may conceive, albeit with a lower probability. 
The Wang study was conducted in young Chinese women and had 
the highest FECHCG/FERT (46.2%) and lowest πCLIN (75.4%) values. 
This may reflect the Bayesian methodology used to detect hCG 
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positive cycles, the identification of DDT (dichlorodiphenyltrichlo-
roethane), present at unusually high levels in this group28, as a 
positive predictor of pre-clinical pregnancy loss29, or even a higher 
incidence of gestational tropho-blastic disease in Asian women30.
The analysis also indicates that fewer hCG pregnancies in the 
Zinaman study (12.5%) failed to progress to clinical recognition, 
compared to either the Wilcox (21.7%) or Wang (24.6%) studies. 
This may reflect differences in methodology for detecting hCG, the 
fact that they made fewer hCG measurements or differences in the 
definition of clinical pregnancy. Wilcox and Wang defined clini-
cal pregnancy as those that lasted for up to 6 weeks after the last 
menstrual period6,8,17,26. In Zinaman, clinical pregnancy was 
determined following serum testing if a woman’s anticipated menses 
was just one day late7. Hence, the window for pre-clinical embryo 
loss was approximately 1–4 weeks post-fertilisation for Wilcox 
and Wang and 1–2 weeks for Zinaman. This different definition of 
clinical pregnancy would not only contribute to the higher πCLIN 
value from Zinaman but also the increased clinical loss of 21.0% 
compared to 12–13% observed by Wilcox and Wang.
Quantifying the outcome of clinical pregnancies is relatively 
straightforward. Excluding those lost to follow-up and induced 
abortions, the probability of a clinical pregnancy progressing to 
a live birth (πLB) was: Wilcox, 87.7% (136/155); Zinaman, 79.0% 
(79/100); and Wang, 87.1% (373/428). Combining these values 
with the modelled πCLIN provides an estimate for embryo loss from 
implantation to live birth of 31.3% (Wilcox), 30.9% (Zinaman) and 
34.2% (Wang) (Table 3).
Estimating embryo loss prior to hCG detection is less straightfor-
ward. For sub-fertile participants, it is impossible to know why 
they struggled to become pregnant: there are many causes of sub- 
fertility31. However, for normally fertile women the modelled hCG 
fecundability values can be used to put limits on fertilisation (πFERT) 
and implantation (πHCG) conditional probabilities. As noted above, 
fecundability is the product of the conditional probabilities of 
success for each stage of the reproductive cycle. Hence for Wang:
FECHCG = πSOC × πFERT × πHCG = 0.462
Since probabilities cannot be greater than 1, the lowest 
possible value for πHCG must be 0.462, indicating a maximum pos-
sible loss from fertilisation up to implantation in these women of 
53.8%. However, it is unlikely that all other probabilities equal 1. 
Sperm-ovum-co-localisation is dependent on both behavioural and 
biological factors. As previously noted, the analyses of Barrett & 
Marshall22,32 and Schwartz23 show that daily intercourse is more 
reproductively effective than alternate day intercourse. Hence, at 
coital frequencies less than once per day, πSOC must be less than 1. 
Specifically, a reduction of fecundability from 0.49 with daily to 
0.39 for alternate day intercourse23 points towards a reduction in 
πSOC of approximately 20%. Volunteers in these hCG studies wished 
to become pregnant and were undoubtedly aware of the importance 
Figure 2. Parameter estimates for fertile and sub-fertile sub-cohorts and associated fecundability values. Values are shown for Wilcox 
( ), Zinaman () and Wang ( ) studies. Panel A shows the proportions in the starting cohorts modelled as fertile or sub-fertile (%fert(1)) & 
%subf(1)). Panel B shows the hCG (FECHCG) and clinical (FECCLIN) fecundabilities and the probability of hCG pregnancies progressing to clinical 
pregnancies (πCLIN). Values are derived from modelled parameter estimates (Table 1) and error bars indicate 95% confidence intervals.
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of well-timed intercourse. However, they were not required to have 
daily intercourse and it is likely that in some of the 3,137 cycles 
intercourse was not always ideally timed. Indeed, in 360/625 cycles 
in the Wilcox study, intercourse occurred from zero to two times 
during the 6 days before ovulation, and intercourse occurred on 
only 40% of the 6 pre-ovulatory days in 625 cycles17. It seems likely 
therefore that πSOC and hence fecundability were not maximised in 
these studies.
Furthermore, not all cycles are ovulatory. Leridon suggested 
that levels of anovulation lie between 5 and 15%33. Among 
normal healthy women, the incidence of anovulation ranged from 
5.5–12.8% depending on the detection method used34. Therefore, 
considering behavioural and biological factors together, it seems 
reasonable to suppose that πSOC < 1.
It also seems unlikely that either fertilisation or implantation prob-
abilities equal 1. Hence, Table 3 shows derived values for πFERT and 
πHCG assuming that πSOC = 0.80, and under conditions where: (i) 
πFERT = 0.90; (ii) πFERT = πHCG; and (iii) πHCG = 0.90. Based on this 
analysis, a plausible range for total embryo loss from fertilisation 
to birth is 40–60%. This is consistent with estimates from both 
older35 and more recent36 text books. Even with the wide range of 
mathematically possible outcomes, it is likely that estimates of 
90%20, 83%37, 80–85%38, 78%1, 76%2 and 70%10,12 total human 
embryonic loss are excessive.
Dataset 1. Raw data Wilcox et al. study
http://dx.doi.org/10.5256/f1000research.9479.d133951
One data file and six control files are provided. The data file is 
saved as csv. and the control files can be read with any simple text 
editor. The readme file provides a data legend.
Dataset 2. Raw data Zinaman et al. study
http://dx.doi.org/10.5256/f1000research.9479.d133952
One data file and six control files are provided. The data file is 
saved as csv. and the control files can be read with any simple text 
editor. The readme files provides a data legend.
Dataset 3. Raw data Wang et al. study
http://dx.doi.org/10.5256/f1000research.9479.d133953
Tne data file and six control files are provided. The data file is 
saved as csv. and the control files can be read with any simple text 
editor. The readme file provides a data legend.
Discussion
In 1980, Schwartz wrote that Barrett & Marshall’s estimate of 
fecundability of 0.68 for daily intercourse “seems to be high”. It 
implies an absolute maximum limit of embryo mortality of 32%. 
Schwartz contrasted this with Leridon’s estimate of 44% embryo 
loss in the first 6 weeks following fertilisation3. However, Leridon’s 
estimates for early intrauterine mortality are substantially depend-
ent on data and analysis from Hertig4,5, which are themselves of 
questionable precision2,13,39. Widespread pessimism about human 
reproductive efficiency may have become a self-fulfilling prophecy 
in the absence of relevant good quality data.
Nevertheless, Schwartz’s analysis is a useful improvement on 
that of Barrett & Marshall and points clearly to the presence of 
infertile or non-viable cycles. The challenge arises in assigning a 
mechanistic cause for this “non-viability”. Previous reports draw 
attention to the difficulty of teasing apart distinct components, 
e.g., egg viability versus uterine receptivity24, or male and female 
factors15, and alternative modelling approaches will yield “differ-
ent interpretations of the parameters related to cycle viability”15. 
The advantage of the present models is that the unit of analysis 
remains the cycle, i.e., fecundability, but the heterogeneity of 
the population is also acknowledged and explicitly incorporated. 
The model for estimating embryo loss also accommodates other 
plausible mechanisms for reproductive failure, rather that accredit-
ing all unaccounted reproductive inefficiency to pre-implantation 
embryo mortality. Although the model does not provide a defini-
tive answer, it does offer plausible limits within which the answer 
may lie.
The results of this analysis offer a statistically clear picture of bi-
modal study populations comprising couples with two discrete 
levels of fertility. This dichotomous division of the study popula-
tions is arguably artificial: it is unlikely to capture all the quan-
titative subtlety that subsists in the original data. Nevertheless, 
expanding the model to three levels does not improve this picture 
and the published data do not support a model of uni-modal, albeit 
varied, fecundability. Put simply, there was a significant propor-
tion of couples in these studies who were, for unknowable reasons, 
infertile or clearly sub-fertile. Incorporation of data derived from 
such couples in calculations to determine normal fecundability will 
therefore result in biased estimates. By analytically separating the 
study population into reproductively normal and sub-fertile sub-
cohorts, more accurate estimates for normal reproductive function 
and embryo mortality have been obtained. Such estimates apply 
primarily to the specific study populations, which are not necessar-
ily fully representative of a general population. The extrapolation 
of quantitative conclusions into other contexts and circumstances 
must always be done with appropriate caution.
The analysis presented here cannot be satisfactorily completed 
owing, in part, to a lack of data on fertilisation success rates 
in vivo40,41. Consequently, the range for pre-implantation loss, at 
approximately 10–40%, is wide, although inclusive of Hertig’s 
pre-implantation loss estimate of 30%4,5. Despite the imperfections 
and weaknesses in the available data, it is apparent that plausible 
values for embryo mortality are considerably less than some figures 
published in the scientific literature. It is concluded that a plausible 
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range for natural human embryo mortality from fertilisation to live 
birth in normal healthy women is approximately 40–60%.
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caution (see review by Prof. Senn ). The use of IVF data to inform our understanding of
natural reproduction can be particularly difficult, as I note elsewhere .
 
Macklon , 2002 :et al.  This is a well-known and frequently cited review. I discuss the
referenced value of 30% elsewhere . However, contrary to what Prof. Trounson seems to
imply, it is neither a summary of nor an extrapolation from IVF data. It is part of Macklon’s “
”, and is copied directly from anoverview of the outcome of spontaneous human pregnancy
earlier review on the “ ”frequency of implantation and early pregnancy loss in natural cycles
by Prof. Tim Chard . Macklon is explicit in stating that the conditions from which  datain vitro
are obtained are “ ” and “ ” . He reviewsfar from ideal do not reflect the normal situation
several hCG studies concluding that many problems associated with these were addressed
by Wilcox  and subsequently Zinaman . Surprisingly however, the numerical estimates in
Macklon (including the 30% survival value) do not reflect the outcome from these two
studies, as I explain elsewhere .
 
McCoy , 2015 :et al.  It is difficult to incorporate quantitative conclusions from McCoy into a
model of natural human embryo loss. All McCoy’s data are from IVF embryos and are
susceptible to criticism regarding their accuracy as a description of natural reproduction. As
he himself states: “specific rates of meiotic and mitotic error reported in this study are likely
” and “particular to the IVF population studies also demonstrated that ovarian stimulation and
” . McCoyIVF culture conditions can both influence rates of chromosome abnormalities
cites Macklon  as authority for a 70% loss of all conceptions in human reproduction.
Moreover, he goes further by associating this loss specifically with “young, otherwise fertile
” .couples
McCoy also cites a published summary  of Edmonds, 1982 , an early hCG study.
Edmonds' data lie at one extreme of the pre-Wilcox studies, with 56.8% of hCG+ cycles
failing prior to clinical recognition. By contrast, Walker, 1988  reported no pre-clinical
losses of hCG+ pregnancies. Neither Edmonds’ nor Walker’s estimates have been
replicated since Wilcox, 1988 . Subsequent studies report a post-implantation, pre-clinical
loss of approximately 20% . Elsewhere , McCoy states that “Fewer than ~30% of
”, citing Wilcox. However, Wilcox  reports that “conceptions result in successful pregnancy
The total rate of pregnancy loss after implantation, including clinically recognized
”.spontaneous abortions, was 31%
Therefore, McCoy’s conclusion that high levels of aneuploidy observed in IVF embryos can
explain natural human embryo loss is not well-founded, since natural embryo loss is
substantially lower than he claims. An alternative view is that the high level of aneuploidy
observed  is, at least in part, an artefact of the handling of human ova and thein vitro
associated interventions of assisted reproductive technology, as suggested by Chard (“it is
possible that at least some of the abnormalities are the result of the experimental
” ) and Braude (“procedures themselves Experiments in our laboratories have suggested
in vitrothat the  handling of oocytes can produce chromosomal aberrations at alarmingly
” ). The critical question is – how large is that part?high frequencies
These issues are addressed in more detail elsewhere .
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This is an interesting and generally well-written article. I am unfamiliar with the field of reproductive
physiology and female fertility regulation and so cannot be described as an expert reviewer. However, I
do have expertise in the field of statistics and modelling and felt to understand the issues much better
having read this article and that is a tribute to its general clarity.
Nevertheless, at one or two points I felt the clarity could have been improved. The author is not always
completely explicit on two points. The first is whether a conditional probability is being estimated (and if so
conditional on what) and the second is the precise details of the mixed model being used.
Since readers will not necessarily be familiar with the software an author uses, and since the more
complex the subject the more likely an algorithm will differ between packages, one of the inevitable
problems in a field of this complexity are 1) that it is quite likely that readers will not be familiar with some
details of implementation and 2) results might differ somewhat from package to package. The author has
used NONMEM, a package that is popular in nonlinear mixed effect modelling in pharmacokinetics but
less well-known in other fields. This is a limitation of the article. (Not because NONMEM is not a suitable
package to use but because it is the only package used.) For example, Makubate and Senn, modelling
 found some differences depending on whether SAS, GenStatthe effects of cross-over trials in infertility,
or R were used to  implement what was ostensibly the same model, or indeed program it from scratch
using Mathcad and in the field of estimating values below the limit of quantitation Senn, Holford and
Hockey got different standard errors using NOMEM compared to SAS, GenStat and R, although such
differences are not necessarily inherent to packages but may reflect implementation.
On a more technical matter, the author has used a discrete mixture which some might regard as being
excessively restrictive and a little unrealistic, although the author does claim "the published data do not
". A further issue is that unlike for causal studies,support a model of uni-modal, albeit varied, fecundability
such as clinical trials, the degree to which the subjects studied are representative of a population of
interest is important. Lacking knowledge of this particular field and the studies cited I cannot judge
whether this condition is satisfied. It seems at least plausible that sub-fertile couples are more likely to be
studied than those of average fertility.
Nevertheless, this seems to be an interesting and valuable exercise in modelling a difficult field.
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I would like to thank Professor Senn for his remarks . I respond to his comments as follows:
Representative Populations: This is an important point and Prof. Senn’s intuitive concern
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3.  
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Representative Populations: This is an important point and Prof. Senn’s intuitive concern
is well-founded. The analysis attempts to introduce a little more focus to the data from the
three particular studies . Despite the similarities between the quantitative conclusions
from the three studies, extrapolation to a general population is risky, given the known and
likely variances in fertility associated with age, health and social status, level of education,
ethnicity etc... However, the strength of these studies lies in the detail and density of the
data, which is rare among other similar studies, and I believe this re-analysis does yield
some additional insight. I have addressed some of the concern regarding differences in
populations and other sources of reproductive variance in another article .
 
Conditional Probabilities: I hope the following makes my intention more explicit.
If P(A|B) is the probability of event A, conditional on event B, then:
(i)     = P(A|B), where A is a live birth, and B is a clinical pregnancyπ
(ii)  = P(A|B), where A is a clinical pregnancy, and B is a positive hCG testπ
(iii)  = P(A|B), where A is a positive hCG test, and B is successful fertilisationπ
(iv)  = P(A|B), where A is successful fertilisation, and B is the  co-localisation ofπ in vivo
ovum and sperm
(v)   = P(A|B), where A is the  co-localisation of ovum and sperm, and B a singleπ in vivo
menstrual cycle
 
Discrete mixture model: I agree that dividing the cohort into two discrete populations is a
little unrealistic. However, in the absence of the original raw data, there is little else that
could be done. The data conform markedly better to this bi-modal distribution, as compared
to either a uni-modal or tri-modal model. I doubt if this model captures all the quantitative
subtlety that subsists in the data; nevertheless, it does both confirm and quantify, albeit
perhaps a little brutally, the clear impression expressed in the original reports that the study
populations included subjects who were sub-fertile.
 
Modelling packages: The point about differing outputs from different modelling software
packages is also well made. My own instinct (which is admittedly not as refined as Prof.
Senn’s) is that any difference is likely to be small, since, although I used NONMEM, there is
no random effect (i.e., OMEGA) modelling other than the residual error variance (i.e.,
SIGMA). However, there are perhaps other reasons why performing the analysis in GenStat
or R is preferable. At some point I will repeat the analysis and report back any differences in
the output.
I shall incorporate changes relating to points 1, 2 and 3 into a second version of the article.
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